Core Insights - Integer Holdings Corporation is participating in the North American Neuromodulation Society Annual Meeting in Las Vegas from January 22 to 25, 2026, showcasing its advancements in neuromodulation and miniaturized active implantable medical devices [1][2]. Group 1: Company Overview - Integer Holdings Corporation is one of the largest medical device contract development and manufacturing organizations (CDMO) globally, serving markets such as cardiac rhythm management and neuromodulation [5]. - The company is recognized as a strategic partner for medical device companies and OEMs, focusing on enhancing patient lives through innovative and high-quality products [5]. Group 2: Product Innovations - At booth 115, Integer will highlight its latest innovations aimed at accelerating development timelines and reducing risks for medical device companies [2]. - The company is showcasing its Xcellion Gen 3 Fast Charge Lithium Ion battery technology, which provides best-in-class runtime and can recharge in as little as 30 minutes [3]. Group 3: Industry Trends - The trend of miniaturization is significantly impacting the future of implantable technologies, with Integer positioning itself as a key player in this transformation [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026. This announcement led to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation, alleging securities fraud and unlawful business practices by the company and its officers [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by February 09, 2026 [2]. - A copy of the complaint related to the lawsuit can be accessed through Pomerantz's website [2]. Group 2: Company Performance - On October 23, 2025, Integer revised its full-year 2025 guidance, projecting net sales growth between -2% to 2% and organic sales growth of 0% to 4% for 2026 [4]. - The company acknowledged that two of its electrophysiology devices faced slower than expected market adoption, which is anticipated to affect demand into 2026 [4]. - Following this announcement, Integer's stock price dropped by $35.22, a decline of 32.28%, closing at $73.89 per share on the same day [4].

Philadelphia, Pennsylvania--(Newsfile Corp. - January 13, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) ("Integer" or the "Company") on behalf of investors who purchased or otherwise acquired Integer securities during the period of July 25, 2024 through October 22, 2025 (the "Class Period"), inclusive.Investor Deadline: Investors who purchased Integer securities during the Class Period may, no ...

Core Insights - Heartland Advisors reported that the Russell 2000® Value Index achieved a return of 3.26% in Q4 2025, outperforming the S&P 500's 2.66% gains, indicating a strong performance for small-cap stocks [1] - The Heartland Value Fund gained 2.61% in the same quarter, underperforming the Russell 2000® Value Index due to stock selection issues, particularly in the healthcare sector [1] Company Analysis: Integer Holdings Corporation (NYSE:ITGR) - Integer Holdings Corporation, a medical device contract development and manufacturing company, closed at $83.57 per share on January 12, 2026, with a market capitalization of $2.93 billion [2] - The stock experienced a one-month return of 13.09% but has lost 39.80% of its value over the past 52 weeks, reflecting significant volatility [2] - Integer's stock fell over 30% in late October 2025 after the company lowered its growth and margin expansion outlook for 2026 due to slower-than-expected market adoption of several products [3] - Management anticipates that these challenges will be temporary, with expectations to outgrow industry peers by 2% and achieve EBIT growth at twice the rate of sales [3]

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue from these products [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decrease of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation for allegedly misleading investors regarding its business operations and sales performance during the specified Class Period [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Integer securities from July 25, 2024, to October 22, 2025 [1][2]. - Investors have until February 9, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Allegations Against the Company - The complaint claims that Integer overstated its competitive positioning in the market [3]. - It alleges that the company experienced undisclosed deterioration in sales of its electrophysiology devices [3]. - The company mischaracterized the key drivers of its growth, leading to a significant stock price drop of $35.22 per share, a decline exceeding 32% in one day following a reduction in sales guidance [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, significantly below analysts' expectations, leading to a stock price drop of $35.22 per share, or over 32%, from $109.11 to $73.89 [6]. - The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, citing slower adoption of two of its EP devices [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled West Palm Beach Firefighters' Pension Fund v. Integer Holdings Corporation, et al., No. 1:25-cv-10251 [3]. - Investors have until February 9, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Allegations - Integer designs and manufactures cardiac rhythm management and cardiovascular products, including electrophysiology devices [4]. - The company allegedly overstated demand for its EP devices while public assurances contradicted the actual decline in demand and revenue from these products [5]. Group 3: Stock Price Impact - On October 23, 2025, Integer lowered its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6]. - The company projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, admitting that two of its EP devices had slower than expected adoption [6]. - Following this announcement, Integer's stock price fell by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [4][5]. Stock Price Decline - On October 23, 2025, Integer announced a reduction in its 2025 sales guidance to between $1.840 billion and $1.854 billion, down from a previous range of $1.850 billion to $1.876 billion, which was below analysts' expectations [6] - The company also projected poor net sales growth of -2% to 2% and organic sales growth of 0% to 4% for 2026, alongside slower adoption rates for two of its EP devices [6] - Following this announcement, Integer's stock price plummeted by $35.22 per share, a decline of over 32%, from $109.11 on October 22, 2025, to $73.89 on October 23, 2025 [6].